NanoSyrinx is a discovery stage biotechnology company developing new therapeutic modalities for Cell & Gene editing. This is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene editing enzymes and nucleases – directly to the cytosol of targeted cells. NanoSyrinx is based at the University of Warwick’s Medical School.
Total raised: $29.81M
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | IQ Capital... | iqcapital.... |
| 23.07.2021 | Octopus Ve... | octopusven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.09.2024 | - | $13.08M | - |
| 11.12.2021 | Seed | $8.23M | - |
| 19.07.2021 | - | $8.5M | - |
Mentions in press and media 12
| Date | Title | Description |
| 10.09.2024 | NanoSyrinx: A New Dawn in Biotech with £10 Million Funding | In the world of biotechnology, innovation is the lifeblood. Today, a new player is making waves. NanoSyrinx, a synthetic biology company based in Coventry, UK, has successfully raised approximately £10 million (around $13 million) in a rece... |
| 10.09.2024 | NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman | Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in ... |
| 10.09.2024 | Biotech firm NanoSyrinx raises £10M for nano syringe delivery platform | Synthetic biotech company NanoSyrinx, developers of nano syringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced that it has closed a £10 million financing round. NanoSyrinx’s platform is b... |
| 10.09.2024 | NanoSyrinx Closes Approx. £10M Financing | NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding. The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing inves... |
| 11.12.2021 | NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platform | NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the ... |
| 19.07.2021 | NanoSyrinx raises £6.2m to develop synthetic biology platform for targeted intracellular engineering | NanoSyrinx raises £6.2m to develop synthetic biology platform for targeted intracellular engineering 19-07-2021 NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a fur... |
| 19.07.2021 | In Five9 deal, Zoom targets growth with customers that cannot afford to get Zoom fatigue | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Video-conferencing software maker Zoom was a big winner of the pandemic, with its name becoming a... |
| 19.07.2021 | NanoSyrinx raises £6.2m to develop synthetic biology platform for targeted intracellular engineering | NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, T... |
| 19.07.2021 | In Five9 deal, Zoom targets growth with customers that cannot afford to get Zoom fatigue | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbofx. Paid Content Harness this metric to drive successful leadership From Indiggo Video-conferencing ... |
| 19.07.2021 | Coventry-based biotech grabs £6.2M funding to develop its novel biologic delivery platform | Coventry-based biotech, NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous in... |
Show more